Cargando…
Facial erythema after the treatment of dupilumab in SLE patient
BACKGROUND: Dupilumab is a receptor antagonist binding to the alpha subunit of the interleukin-4 receptor. Through binding to it, dupilumab inhibits signaling of both IL-4 and IL-13, the representative Th2 biomarkers. Recently, in addition to the treatment effects for atopic dermatitis (AD), there i...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7491356/ https://www.ncbi.nlm.nih.gov/pubmed/32944024 http://dx.doi.org/10.1186/s13223-020-00458-6 |
_version_ | 1783582204369043456 |
---|---|
author | Jang, Dong Hyek Lee, Jae In Bae, Joo Yoon Jung, Hye Jung Park, Mi Yeon Ahn, Jiyoung |
author_facet | Jang, Dong Hyek Lee, Jae In Bae, Joo Yoon Jung, Hye Jung Park, Mi Yeon Ahn, Jiyoung |
author_sort | Jang, Dong Hyek |
collection | PubMed |
description | BACKGROUND: Dupilumab is a receptor antagonist binding to the alpha subunit of the interleukin-4 receptor. Through binding to it, dupilumab inhibits signaling of both IL-4 and IL-13, the representative Th2 biomarkers. Recently, in addition to the treatment effects for atopic dermatitis (AD), there is an emerging adverse event as facial erythema. CASE PRESENTATION: A twenty-seven-year-old female patient developed erythema and desquamation on the face and neck after dupilumab administration. She had AD on her arms, legs, and trunk before the treatment but there was no atopic clinical feature in her face and neck. With the treatment of dupilumab, her skin lesions of the body have improved from the beginning of the treatment. In the patch test, including dupilumab, there was no specific finding other than the 1+ response to neomycin on day 2. In the intradermal test to dupilumab, a positive result was observed 15 min later, but negative both days 1 and 2. The blood examination showed an elevation of both ANA as 1:80 and anti-phospholipid antibodies (Anti-cardiolipin IgM, IgG, and Anti- beta 2 GPI IgG). She was diagnosed with Systemic lupus erythematosus (SLE) based on diagnostic criteria by a rheumatologist. CONCLUSION: Dupilumab is an emerging therapeutic agent for AD, and treatment cases are increasing in Korea. However, there are several adverse events during the treatment of dupilumab. Herein, we report the unexpected adverse event during the treatment of dupilumab in SLE patients. |
format | Online Article Text |
id | pubmed-7491356 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-74913562020-09-16 Facial erythema after the treatment of dupilumab in SLE patient Jang, Dong Hyek Lee, Jae In Bae, Joo Yoon Jung, Hye Jung Park, Mi Yeon Ahn, Jiyoung Allergy Asthma Clin Immunol Case Report BACKGROUND: Dupilumab is a receptor antagonist binding to the alpha subunit of the interleukin-4 receptor. Through binding to it, dupilumab inhibits signaling of both IL-4 and IL-13, the representative Th2 biomarkers. Recently, in addition to the treatment effects for atopic dermatitis (AD), there is an emerging adverse event as facial erythema. CASE PRESENTATION: A twenty-seven-year-old female patient developed erythema and desquamation on the face and neck after dupilumab administration. She had AD on her arms, legs, and trunk before the treatment but there was no atopic clinical feature in her face and neck. With the treatment of dupilumab, her skin lesions of the body have improved from the beginning of the treatment. In the patch test, including dupilumab, there was no specific finding other than the 1+ response to neomycin on day 2. In the intradermal test to dupilumab, a positive result was observed 15 min later, but negative both days 1 and 2. The blood examination showed an elevation of both ANA as 1:80 and anti-phospholipid antibodies (Anti-cardiolipin IgM, IgG, and Anti- beta 2 GPI IgG). She was diagnosed with Systemic lupus erythematosus (SLE) based on diagnostic criteria by a rheumatologist. CONCLUSION: Dupilumab is an emerging therapeutic agent for AD, and treatment cases are increasing in Korea. However, there are several adverse events during the treatment of dupilumab. Herein, we report the unexpected adverse event during the treatment of dupilumab in SLE patients. BioMed Central 2020-07-03 /pmc/articles/PMC7491356/ /pubmed/32944024 http://dx.doi.org/10.1186/s13223-020-00458-6 Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Case Report Jang, Dong Hyek Lee, Jae In Bae, Joo Yoon Jung, Hye Jung Park, Mi Yeon Ahn, Jiyoung Facial erythema after the treatment of dupilumab in SLE patient |
title | Facial erythema after the treatment of dupilumab in SLE patient |
title_full | Facial erythema after the treatment of dupilumab in SLE patient |
title_fullStr | Facial erythema after the treatment of dupilumab in SLE patient |
title_full_unstemmed | Facial erythema after the treatment of dupilumab in SLE patient |
title_short | Facial erythema after the treatment of dupilumab in SLE patient |
title_sort | facial erythema after the treatment of dupilumab in sle patient |
topic | Case Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7491356/ https://www.ncbi.nlm.nih.gov/pubmed/32944024 http://dx.doi.org/10.1186/s13223-020-00458-6 |
work_keys_str_mv | AT jangdonghyek facialerythemaafterthetreatmentofdupilumabinslepatient AT leejaein facialerythemaafterthetreatmentofdupilumabinslepatient AT baejooyoon facialerythemaafterthetreatmentofdupilumabinslepatient AT junghyejung facialerythemaafterthetreatmentofdupilumabinslepatient AT parkmiyeon facialerythemaafterthetreatmentofdupilumabinslepatient AT ahnjiyoung facialerythemaafterthetreatmentofdupilumabinslepatient |